A kockázatmegosztás szerepe a gyógyszerek finanszírozásában

Translated title of the contribution: The role of risk sharing in drug funding

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In order to make the pharmaceutical budget predictable, an internationally accepted approach of health insurance providers is to shift more and more financial risks to pharmaceutical companies. The major paradox of financial risk-sharing schemes is that increased mortality, poor therapeutic compliance, reduced access to healthcare services, decreasing quality of health care and lack of treatment reduce pharmaceutical spending. Consequently, payers have started to employ reimbursement schemes that enable them to guarantee health gain and quality of service. Introduction of a risk-sharing scheme based on outcome and compliance can be a major advancement in the strategy of the Hungarian National Health Insurance Fund (NHIF). Funding schemes that guarantee therapeutic benefit can help reduce the uncertainty in coverage decisions regarding high-value, innovative healthcare technologies. However, justification of the parallel use of financial and outcomebased risk-sharing on the micro level is questionable. Even if the primary objective of the NHIF is to ensure the sustainbility of the public pharmaceutical budget, financial risks should be managed on the macro level.

Original languageHungarian
Pages (from-to)237-241
Number of pages5
JournalLege Artis Medicinae
Volume20
Issue number3-4
Publication statusPublished - Apr 2010

Fingerprint

Financial Risk Sharing
National Health Programs
Budgets
Pharmaceutical Preparations
Delivery of Health Care
Quality of Health Care
Health Insurance
Compliance
Uncertainty
Technology
Mortality
Health
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A kockázatmegosztás szerepe a gyógyszerek finanszírozásában. / Kaló, Z.; Vokó, Z.

In: Lege Artis Medicinae, Vol. 20, No. 3-4, 04.2010, p. 237-241.

Research output: Contribution to journalArticle

@article{c3cb66aee0904b6eb856a2291d25196f,
title = "A kock{\'a}zatmegoszt{\'a}s szerepe a gy{\'o}gyszerek finansz{\'i}roz{\'a}s{\'a}ban",
abstract = "In order to make the pharmaceutical budget predictable, an internationally accepted approach of health insurance providers is to shift more and more financial risks to pharmaceutical companies. The major paradox of financial risk-sharing schemes is that increased mortality, poor therapeutic compliance, reduced access to healthcare services, decreasing quality of health care and lack of treatment reduce pharmaceutical spending. Consequently, payers have started to employ reimbursement schemes that enable them to guarantee health gain and quality of service. Introduction of a risk-sharing scheme based on outcome and compliance can be a major advancement in the strategy of the Hungarian National Health Insurance Fund (NHIF). Funding schemes that guarantee therapeutic benefit can help reduce the uncertainty in coverage decisions regarding high-value, innovative healthcare technologies. However, justification of the parallel use of financial and outcomebased risk-sharing on the micro level is questionable. Even if the primary objective of the NHIF is to ensure the sustainbility of the public pharmaceutical budget, financial risks should be managed on the macro level.",
author = "Z. Kal{\'o} and Z. Vok{\'o}",
year = "2010",
month = "4",
language = "Hungarian",
volume = "20",
pages = "237--241",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "3-4",

}

TY - JOUR

T1 - A kockázatmegosztás szerepe a gyógyszerek finanszírozásában

AU - Kaló, Z.

AU - Vokó, Z.

PY - 2010/4

Y1 - 2010/4

N2 - In order to make the pharmaceutical budget predictable, an internationally accepted approach of health insurance providers is to shift more and more financial risks to pharmaceutical companies. The major paradox of financial risk-sharing schemes is that increased mortality, poor therapeutic compliance, reduced access to healthcare services, decreasing quality of health care and lack of treatment reduce pharmaceutical spending. Consequently, payers have started to employ reimbursement schemes that enable them to guarantee health gain and quality of service. Introduction of a risk-sharing scheme based on outcome and compliance can be a major advancement in the strategy of the Hungarian National Health Insurance Fund (NHIF). Funding schemes that guarantee therapeutic benefit can help reduce the uncertainty in coverage decisions regarding high-value, innovative healthcare technologies. However, justification of the parallel use of financial and outcomebased risk-sharing on the micro level is questionable. Even if the primary objective of the NHIF is to ensure the sustainbility of the public pharmaceutical budget, financial risks should be managed on the macro level.

AB - In order to make the pharmaceutical budget predictable, an internationally accepted approach of health insurance providers is to shift more and more financial risks to pharmaceutical companies. The major paradox of financial risk-sharing schemes is that increased mortality, poor therapeutic compliance, reduced access to healthcare services, decreasing quality of health care and lack of treatment reduce pharmaceutical spending. Consequently, payers have started to employ reimbursement schemes that enable them to guarantee health gain and quality of service. Introduction of a risk-sharing scheme based on outcome and compliance can be a major advancement in the strategy of the Hungarian National Health Insurance Fund (NHIF). Funding schemes that guarantee therapeutic benefit can help reduce the uncertainty in coverage decisions regarding high-value, innovative healthcare technologies. However, justification of the parallel use of financial and outcomebased risk-sharing on the micro level is questionable. Even if the primary objective of the NHIF is to ensure the sustainbility of the public pharmaceutical budget, financial risks should be managed on the macro level.

UR - http://www.scopus.com/inward/record.url?scp=77951545751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951545751&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 237

EP - 241

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 3-4

ER -